Watch for the launch of ISOPP’s virtual education program on Oncology Pharmacotherapy and Applications of Biosimilars in 2021; made possible through an educational grant from Pfizer.
Recognizing that there is a rapid expansion of Biosimilars usage in clinical practice, and that the role of an oncology pharmacist is evolving and further integrating as a key member of a multidisciplinary healthcare team, ISOPP is developing an online education program that supports oncology pharmacists to safely and confidently introduce Biosimilars into their clinical practice and multidisciplinary healthcare team. ISOPP will present this education program in a novel way by giving both fundamentals and advanced aspects of 1) pharmacotherapy of various cancers, 2) implementation of biosimilars in oncology practice and 3) interpretation of available scientific and regulatory data and pharmacist’s recommendations for using biosimilars in different cancers.
The program is aimed at oncology pharmacists who have practiced for at least one year in the area of oncology pharmacy, and will consist of 10 online courses (25 hours) and an opportunity to meet at ISOPP’s 2022 Symposium in Spain to expand the Biosimilars Expert Network.
Click on the module topic below for more details on the authors and module learning objectives.
- Fundamentals of Biosimilars use in contemporary oncology clinical practice
- Fundamentals in oncology pharmacy practice
- Management of breast cancer
- Management of colorectal cancer
- Management of lung cancer
- Management of gynecological cancer
- Management of upper GI cancers
- Management of kidney cancer
- Cancer supportive care management
- Implementation of Biosimilars in clinical practice